[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100505700":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":30,"responsibleParty":72,"collaborators":20,"id":74,"slug":20,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":20,"enrollmentInfo":83,"targetDuration":20,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":32,"whyStopped":20,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"University Medical Center Groningen","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Screening population","EXPERIMENTAL","Patients with newly diagnosed stage IV non-oncogene addicted NSCLC, who are fit for systemic treatment and don't have any symptoms of brain disease.",[13],"Diagnostic Test: MRI",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","MRI","MRI scan of the brain",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"F. Bensch, MD, PhD","CONTACT","0031503616161","f.bensch@umcg.nl",{"name":28,"role":24,"phone":25,"phoneExt":20,"email":29},"L.B.M. Hijmering, MD","l.b.m.hijmering-kappelle@umcg.nl",[31,46,59],{"facility":5,"status":32,"city":33,"state":34,"zip":35,"country":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Groningen","Provincie Groningen","9713LZ","Netherlands",{"type":38,"coordinates":39},"Point",[40,41],6.56667,53.21917,{"lat":41,"lon":40},[44],{"name":45,"role":24,"phone":20,"phoneExt":20,"email":20},"Frederike Bensch, MD, PhD",{"facility":47,"status":32,"city":48,"state":20,"zip":20,"country":36,"cosmosGeoPoint":49,"geoPoint":53,"contacts":54},"Maastricht UMC+","Maastricht",{"type":38,"coordinates":50},[51,52],5.68889,50.84833,{"lat":52,"lon":51},[55],{"name":56,"role":24,"phone":20,"phoneExt":57,"email":58},"Lizza Hendriks","+314338750","lizza.hendriks@mumc.nl",{"facility":60,"status":32,"city":61,"state":20,"zip":20,"country":36,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Ommelander Ziekenhuisgroep","Scheemda",{"type":38,"coordinates":63},[64,65],6.97222,53.17333,{"lat":65,"lon":64},[68],{"name":69,"role":24,"phone":70,"phoneExt":20,"email":71},"Alice Staats","031652724738","a.niemeijer@ozg.nl",{"type":73,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100505700",false,"NCT05864794","Value of Screening MRI Brain in Stage IV Non-small Cell Lung Cancer","ValUe of Screening MRI Brain in Patients With Newly Diagnosed Stage IV Non-oncogene Addicted Non-small Cell Lung CANcer - The VULCAN Trial","VULCAN","Inclusion Criteria:\n\n* Histologically or cytologically confirmed stage IV metastatic NSCLC, not amenable to curative treatment.\n* Fit for systemic treatment (PS 0-2) according to standard of care.\n* No symptoms of brain disease disease assessed according to standard clinical care by the thoracic oncologist.\n\nExclusion Criteria:\n\n* Prior\u002Fconcomitant therapy for stage IV disease.\n* Oncogenic diver mutation (e.g. EGFR, ALK, ROS1, RET, MET, and BRAF) with approved targeted treatment.\n* Contraindications for MRI scan with contrast as per standard of care protocol of the institution.","ALL","18 Years",{"count":84,"type":85},100,"ESTIMATED","INTERVENTIONAL",[88],"NA","Patients with newly diagnosed stage IV non-oncogene addicted NSCLC, who are fit for systemic treatment and don't have any symptoms of brain disease will undergo an MRI of the brain to screen for brain disease.",[91],"Non Small Cell Lung Cancer Metastatic",[93,94],"brain metastasis","screening","2026-06-08",{"date":97,"type":98},"2026-06-09","ACTUAL",{"date":100,"type":98},"2024-05-13",{"date":102,"type":85},"2028-12-31",{"name":5,"class":6},3]